Upgrade to SI Premium - Free Trial

2022 Product Launches Will Provide Good Foundation for Bristol-Myers Squibb's (BMY) Future Growth, Reiterate Outperform - BMO Capital

February 4, 2022 7:49 AM
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $72.00 price target on Bristol-Myers Squibb Co. (NYSE: BMY) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Trader Talk

Next Articles